|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|By mouth, intravenous, intramuscular|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||384.425 g·mol−1|
|3D model (JSmol)|
|(what is this?) (verify)|
Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.
The most common side effects include kidney failure requiring dialysis, hemoglobinuria (the presence of hemoglobin in urine) and jaundice.
Artesunate is generally well tolerated. Side effects may include a slow heartbeat, allergic reaction, dizziness, and low white blood cell levels. During pregnancy it appears to be a safer option, even though animal studies have found harm to the baby. Use is likely fine during breastfeeding. It is in the artemisinin class of medication.
Artesunate was developed by Liu Xu in 1977. It is on the World Health Organization's List of Essential Medicines. It was approved for medical use in the United States in May 2020. It is in the class of medications known as artemisinins, which are derivatives from "qinghao," or sweet wormwood plant (Artemisia annua).
Artesunate is the first-line treatment for children or adults with severe malaria, usually in combination with another antimalarial drug. There is moderate-quality evidence that treatment with artesunate plus mefloquine is superior to treatment with artesunate plus amodiaquine or artesunate plus sulfadoxine-pyrimethamine. Artemisinin-based combination therapy may be used by mouth in persons that can tolerate it after 24 hours by injection.[medical citation needed]
Artesunate is preferred over parenteral quinine for severe malaria treatment. Artesunate was shown to prevent more deaths from severe malaria than quinine in two large multicentre randomized controlled trials from Africa and Asia. A subsequent systematic review of seven randomized controlled trials found this improvement in survival rates to be consistent across all trials.
Artesunate's efficacy is comparable to that of artemether, another artemisinin derivative, in treating adults for severe malaria caused by Plasmodium falciparum, though artesunate clears more parasites initially. Artesunate combination drugs have a number of advantages over artemether-based drugs in terms of its uptake and administration routes and may be more effective in treatment of severe and complicated malaria in children.
Artesunate is also used to treat less severe forms of malaria when it can be given orally. It has activity against P. ovale, P. malariae, and severe P. knowlesi.
Artesunate + sulfadoxine/pyrimethamine for treatment of P. vivax is not recommended due to high rates of resistance.
While artesunate is used primarily as treatment for malaria, there is some evidence that it may also have some beneficial effects in Schistosoma haematobium infection, but has not been evaluated in large randomized trials.
Artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinine.
When given in the second or third trimesters of pregnancy, no artesunate-related adverse pregnancy outcomes have been reported. However, there is insufficient evidence regarding the safety of artesunate use in the first trimester of pregnancy. The WHO recommends that artesunate use for severe malaria in the first trimester should be based on the individual risks versus benefits. In absence of other viable treatment options, artesunate may be used.[medical citation needed]
Artesunate is safe for use in children. Artesunate + sulfadoxine/pyrimethamine should be avoided in the newborns due to sulfadoxine/pyrmethamine effects on bilirubin. Parenteral artesunate dosing for treatment of severe malaria in children less than 20 kg should be higher than that of adults in order to increase exposure. When artesunate cannot be given orally or intramuscularly due to an individual's weakness or inability to swallow, rectal administration may be given as pre-referral treatment as long as parenteral administration is initiated after transfer to a more advanced facility.[medical citation needed]
Artesunate may cause serious side effects including hemolytic anemia (a condition in which red blood cells are destroyed), and severe allergic reactions.
Artesunate is generally safe and well tolerated. Artesunate-based regimens are less likely to cause vomiting and tinnitus than quinine plus anti-malarial antibiotic therapy. The best recognised adverse effect of the artemisinins is that they lower reticulocyte counts. This is not usually of clinical relevance.[medical citation needed]
With increased use of I.V. artesunate, there have been reports of post-artesunate delayed haemolysis (PADH). Delayed haemolysis (occurring around two weeks after treatment) has been observed in people treated with artesunate for severe malaria.
Artesunate is typically a well tolerated medicine. Known contraindications include a previous severe allergic reaction to artesunate.
Drugs that should be avoided while on artesunate are the drugs that inhibit the liver enzyme CYP2A6. These drugs include amiodarone, desipramine, isoniazid, ketoconazole, letrozole, methoxsalen and tranylcypromine.
Mechanisms of action
The mechanisms of action of artesunate remains unclear and debatable. Artesunate is a prodrug that is rapidly converted to its active form dihydroartemisinin (DHA). This process involves hydrolysis of the 4-carbon ester group via plasma esterase enzyme. It is hypothesized that the cleavage of endoperoxide bridge in the pharmacophore of DHA generates reactive oxygen species (ROS), which increases oxidative stress and causes malarial protein damage via alkylation. In addition, Artesunate potently inhibits the essential Plasmodium falciparum exported protein 1 (EXP1), a membrane glutathione S-transferase. As a result, the amount of glutathione in the parasite is reduced.[medical citation needed]
In 2016, artemisinin has been shown to bind to a large number targets, suggesting that it acts in a promiscuous manner. There is evidence suggesting DHA inhibition of calcium-dependent ATPase on endoplasmic membrane, which disrupts protein folding of parasites.
In infected individuals, the elimination half-life of artesunate is about 0.22 hours. Its active metabolite, DHA, has a slightly longer half-life of 0.34 hours. Overall, the average half-life ranges from 0.5 to 1.5 hours. Because of its short half-life, its use in malaria prevention is limited.
DHA is metabolized to an inactive metabolite by the liver enzymes CYP2B6, CYP2C19, and CYP3A4.
Artesunate is made from dihydroartemisinin (DHA) by reacting it with succinic acid anhydride in a basic medium. It is one of few semi-synthetic derivatives from artemisinin that is water-soluble.
In 2007, the FDA approved an Investigational New Drug (IND) protocol for intravenous artesunate.[medical citation needed]
Artesunate is under study for the treatment of cancer and COVID-19.
In May 2020, artesunate was approved for medical use in United States. Prior to this approval, intravenous (IV) artesunate was only available through the Expanded Access program of the U.S. Food and Drug Administration (FDA), which allowed the Centers for Disease Control and Prevention (CDC) to provide IV artesunate to people in the U.S. with severe malaria and to people with uncomplicated malaria who are unable to take oral medications under an investigational new drug (IND) protocol. There has been no FDA-approved drug for treatment of severe malaria in the United States since the marketing of quinidine was discontinued by the manufacturer in March 2019.
The safety and efficacy of IV artesunate for the treatment of severe malaria was primarily evaluated in a randomized controlled trial in Asia (Trial 1) and a supportive published randomized controlled trial in Africa (Trial 2). Trial 1 was conducted at 10 sites in Myanmar, Bangladesh, India, and Indonesia.
Trial 1 enrolled 1,461 participants who received either IV artesunate or the comparator drug quinine and included 202 pediatric participants younger than 15 years. Trial 2 included 5,425 randomized pediatric participants younger than 15 years of age with severe malaria who were treated with artesunate or quinine. In both trials, the number of participants treated with artesunate who died in the hospital was significantly lower than the number who died in the control group treated with quinine. Trial 2 was conducted during 2005–2010 in nine African countries. A third trial, Trial 3, was conducted during 2007–2008 in Gabon and Malawi.
In Trial 1, the most common adverse reactions in participants with malaria treated with IV artesunate were acute renal failure requiring dialysis, hemoglobinuria and jaundice. The safety profile in Trial 2 was generally similar to Trial 1.
One trial was used to evaluate both, safety and benefits of artesunate. The trial enrolled participants with severe malaria who needed hospitalization because of their condition. Participants received at random either artesunate or a medicine used to treat malaria (quinine). Participants and the health care providers knew which treatment was being given.
The benefit of artesunate in comparison to quinine was evaluated by comparing the number of participants who died while in the hospital (in-hospital mortality).
The benefit of artesunate was supported by the data from Trial 2 in which pediatric participants younger than 15 years of age with severe malaria were randomly assigned treatment with artesunate or quinine.
The application for IV artesunate was granted priority review and orphan drug designations. The FDA granted approval of artesunate for injection to Amivas.
- ^ "Artesunate definition". Drugs.com. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
- ^ "Artesunate". Drugs.com. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
- ^ a b "Artesunate for injection safely and effectively. See full prescribing information for Artesunate for injection. Artesunate for injection, for intravenous use Initial U.S. Approval: 2020". DailyMed. 5 November 2021. Retrieved 11 March 2022.
- ^ a b c d e f "Intravenous Artesunate for Treatment of Severe Malaria in the United States". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 29 October 2016. Retrieved 28 October 2016.
- ^ a b c d e "Artesunate" (PDF). World Health Organization. March 2013. Archived from the original (PDF) on 28 December 2013. Retrieved 7 December 2016.
- ^ a b Rosenthal PJ (April 2008). "Artesunate for the treatment of severe falciparum malaria". The New England Journal of Medicine. 358 (17): 1829–1836. doi:10.1056/NEJMct0709050. PMID 18434652. S2CID 8480109.
- ^ World Health Organization (October 2018). Rectal artesunate for pre-referral treatment of severe malaria. Global Malaria Programme (Report). World Health Organization. hdl:10665/259356. WHO/HTM/GMP/2017.19; License: CC BY-NC-SA 3.0 IGO.
- ^ a b c d e f g h i j k l This article incorporates text from this source, which is in the public domain: "Drug Trials Snapshots: Artesunate". U.S. Food and Drug Administration (FDA). 26 May 2020. Retrieved 5 June 2020.
- ^ Kovacs SD, Rijken MJ, Stergachis A (February 2015). "Treating severe malaria in pregnancy: a review of the evidence". Drug Safety. 38 (2): 165–181. doi:10.1007/s40264-014-0261-9. PMC 4328128. PMID 25556421.
- ^ "Artesunate use while Breastfeeding | Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 7 December 2016.
- ^ Li G, Li Y, Li Z, Zeng M (28 November 2017). Artemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them. Academic Press. ISBN 9780128132111.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b c d e f g h i j k l This article incorporates text from this source, which is in the public domain: "FDA Approves Only Drug in U.S. to Treat Severe Malaria". U.S. Food and Drug Administration (FDA) (Press release). 26 May 2020. Retrieved 26 May 2020.
- ^ This article incorporates text from this source, which is in the public domain: Centers for Disease Control and Prevention (August 2007). "Notice to Readers: New Medication for Severe Malaria Available Under an Investigational New Drug Protocol" (PDF). MMWR Morb. Mortal. Wkly. Rep. 56 (30): 769–70.
- ^ a b c d e f World Health Organization (April 2015). Guidelines for treatment of malaria. WHO Guidelines Approved by the Guidelines Review Committee (3rd ed.). Geneva: World Health Organization. hdl:10665/162441. ISBN 9789241549127. PMID 26020088.
- ^ "CDC: Artesunate Now First-Line Treatment for Severe Malaria in the United States". U.S. Centers for Disease Control and Prevention (CDC) (Press release). 28 March 2019. Retrieved 6 April 2019.
- ^ "Treatment of Malaria: Guidelines For Clinicians (United States)". U.S. Centers for Disease Control and Prevention (CDC). 8 February 2009. Retrieved 30 May 2020.
- ^ Peixoto HM, Marchesini PB, de Oliveira MR (November 2016). "Efficacy and safety of artesunate-mefloquine therapy for treating uncomplicated Plasmodium falciparum malaria: systematic review and meta-analysis". Transactions of the Royal Society of Tropical Medicine and Hygiene. 110 (11): 626–636. doi:10.1093/trstmh/trw077. PMID 28039388.
- ^ Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. (November 2010). "Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial". Lancet. 376 (9753): 1647–1657. doi:10.1016/S0140-6736(10)61924-1. PMC 3033534. PMID 21062666.
- ^ Dondorp A, Nosten F, Stepniewska K, Day N, White N (2005). "Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial". Lancet. 366 (9487): 717–725. doi:10.1016/S0140-6736(05)67176-0. PMID 16125588. S2CID 173027.
- ^ Sinclair D, Donegan S, Isba R, Lalloo DG (June 2012). "Artesunate versus quinine for treating severe malaria". The Cochrane Database of Systematic Reviews. 6 (6): CD005967. doi:10.1002/14651858.CD005967.pub4. PMC 6532684. PMID 22696354.
- ^ Phu NH, Tuan PQ, Day N, Mai NT, Chau TT, Chuong LV, et al. (April 2010). "Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria". Malaria Journal. 9 (1): 97. doi:10.1186/1475-2875-9-97. PMC 2873528. PMID 20398339.
- ^ Li Q, Weina P (July 2010). "Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria". Pharmaceuticals. 3 (7): 2322–2332. doi:10.3390/ph3072322. PMC 4036668. PMID 27713355.
- ^ Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme JL, et al. (February 2007). "Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks" (PDF). Transactions of the Royal Society of Tropical Medicine and Hygiene. 101 (2): 113–116. doi:10.1016/j.trstmh.2006.03.003. PMID 16765398. S2CID 1675813.
- ^ WHO (2007). Assessment of the safety of artemisinin compounds in pregnancy Archived 14 April 2010 at the Wayback Machine. World Health Organization, Geneva.
- ^ Song T, Chen J, Huang L, Gan W, Yin H, Jiang J, et al. (March 2016). "Should we abandon quinine plus antibiotic for treating uncomplicated falciparum malaria? A systematic review and meta-analysis of randomized controlled trials". Parasitology Research. 115 (3): 903–912. doi:10.1007/s00436-015-4842-z. PMID 26661109. S2CID 18501106.
- ^ Clark RL (February 2012). "Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients". Birth Defects Research. Part A, Clinical and Molecular Teratology. 94 (2): 61–75. doi:10.1002/bdra.22868. PMID 22125126.
- ^ Boillat O, Spechbach H, Chalandon Y, Eperon G (2015). "Post-artesunate delayed haemolysis ‒ report of four cases and review of the literature". Swiss Medical Weekly. 145 (4546): w14181. doi:10.4414/smw.2015.14181. PMID 26524733.
- ^ Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, et al. (June 2014). "Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study". The Journal of Infectious Diseases. 209 (12): 1921–1928. doi:10.1093/infdis/jit841. PMID 24376273.
- ^ Hess KM, Goad JA, Arguin PM (1 January 2010). "Intravenous artesunate for the treatment of severe malaria". The Annals of Pharmacotherapy. 44 (7–8): 1250–1258. doi:10.1345/aph.1M732. PMID 20551300. S2CID 23946665. Archived from the original on 10 November 2016.
- ^ "Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]" (PDF). Sanofi-Aventis. Archived (PDF) from the original on 24 October 2016.
- ^ a b c d Cui L, Su XZ (October 2009). "Discovery, mechanisms of action and combination therapy of artemisinin". Expert Review of Anti-Infective Therapy. 7 (8): 999–1013. doi:10.1586/eri.09.68. PMC 2778258. PMID 19803708.
- ^ Lisewski AM, Quiros JP, Ng CL, Adikesavan AK, Miura K, Putluri N, et al. (August 2014). "Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate". Cell. 158 (4): 916–928. doi:10.1016/j.cell.2014.07.011. PMC 4167585. PMID 25126794.
- ^ Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, et al. (December 2015). "Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum". Nature Communications. 6: 10111. Bibcode:2015NatCo...610111W. doi:10.1038/ncomms10111. PMC 4703832. PMID 26694030.
- ^ a b Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L (September 2011). "Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration". Malaria Journal. 10: 263. doi:10.1186/1475-2875-10-263. PMC 3180444. PMID 21914160.
- ^ Hess KM, Goad JA, Arguin PM (1 July 2010). "Intravenous artesunate for the treatment of severe malaria". The Annals of Pharmacotherapy. 44 (7–8): 1250–1258. doi:10.1345/aph.1M732. PMID 20551300. S2CID 23946665.
- ^ "World of Chemicals – online chemical directory, chemistry portal, articles, news". www.worldofchemicals.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- ^ "Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017.
- ^ Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, et al. (January 2021). "Repurposing Antimalarials to Tackle the COVID-19 Pandemic". Trends in Parasitology. 37 (1): 8–11. doi:10.1016/j.pt.2020.10.003. PMC 7572038. PMID 33153922.
- ^ "Drug Approval Package: Artesunate". U.S. Food and Drug Administration (FDA). 25 June 2020. Retrieved 24 September 2020.
- ^ "Artesunate Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 5 September 2017. Retrieved 27 May 2020.
- "Artesunate". Drug Information Portal. U.S. National Library of Medicine.